Sanofi (SNY)
(Delayed Data from NSDQ)
$47.53 USD
-0.91 (-1.88%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $47.54 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.53 USD
-0.91 (-1.88%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $47.54 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth C Momentum C VGM
Zacks News
Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Alkermes plc (ALKS) incurred narrower than expected loss in Q2 but marginally surpassed sales estimates. The company reiterated its 2017 outlook.
Bayer (BAYRY) Q2 Earnings Beat, Sales Miss, Cuts Guidance
by Zacks Equity Research
Bayer AG (BAYRY) topped earnings but missed sales expectations in Q2. The company also lowered its guidance for full-year 2017.
Bristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View
by Zacks Equity Research
Bristol-Myers (BMY) reports encouraging second-quarter results, beating both earnings and sales estimates.
Alexion (ALXN) Tops Q2 Earnings & Revenues, Ups 2017 View
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) exceeded both earnings and revenue estimates in Q2 and also raised its 2017 guidance.
Amgen (AMGN) Stock Falls Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Amgen Inc. (AMGN) beat estimates on both earnings & sales in Q2. While Amgen slightly tightened the sales guidance, it raised the earnings outlook backed by its strong performance in the first half.
Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed
by Zacks Equity Research
Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares.
Merck's Biosimilar Insulin Gets Tentative FDA Approval
by Zacks Equity Research
Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.
Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod
by Arpita Dutt
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.
Sarepta & BioMarin Settle Patent Litigation on Exon Skipping
by Zacks Equity Research
Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy therapies.
Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt
by Zacks Equity Research
Valeant (VRX) has decided to sell Obagi Medical for $190 million and use the proceeds for reducing down debt.
Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Cyramza, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Perrigo Company Gets FDA Approval for Generic Topical Gel
by Zacks Equity Research
Perrigo Company plc (PRGO) receives approval from the FDA for generic version of Androgel Topical Gel, for replacement therapy in males.
Early Read on the Q2 Earnings Season
by Sheraz Mian
I am reasonably confident that we are on our way for another reassuring earnings read.
AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise
by Zacks Equity Research
AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).
Foreign Stock Roundup: Infosys Beats, Taiwan Semiconductor Misses
by Swarup Gupta
Dovish comments from Yellen helped global stocks post gains.
Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit
by Zacks Equity Research
Emergent BioSolutions Inc. (EBS) announced that it has inked an agreement to acquire the FDA-licensed smallpox vaccine's business of Sanofi (SNY) in an all-cash deal of up to $125 million.
Pfizer Xeljanz Label Expansion Application Accepted by FDA
by Zacks Equity Research
Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) for Xeljanz has been accepted for review by the FDA.
Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.
by Arpita Dutt
Novartis (NVS) was in the limelight this week with its CAR-T cell therapy receiving the support of an FDA advisory panel.
Mallinckrodt's MNK-1411 Gets Orphan Drug Status for DMD
by Zacks Equity Research
Mallinckrodt plc (MNK) announced that the FDA has granted orphan drug designation to its pipeline candidate - MNK-1411, which is being evaluated for the treatment of Duchenne muscular dystrophy (DMD).
Lilly Settles Patent Litigation on Cialis with Generic Firms
by Zacks Equity Research
Eli Lilly & Company (LLY) announced that it has entered into an agreement with generic companies to settle a patent relating to its erectile dysfunction drug Cialis (tadalafil).
Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform
by Zacks Equity Research
We issued an updated research report Endocyte, Inc. (ECYT) on Jul 12.
Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth
by Zacks Equity Research
On Jul 11, Alnylam Pharmaceuticals Inc. (ALNY) was upgraded to a Zacks Rank #2 (Buy).
Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) specialty care global business unit, Genzyme, announced encouraging results from the ongoing phase II open-label extension (OLE) study.
Sanofi to Buy Vaccine Biotech Protein Sciences for $650M
by Zacks Equity Research
Sanofi (SNY), on Monday, announced plans to buy a Meriden, CT-based private vaccine biotech, Protein Sciences for an upfront payment of $650 million.
Are Medicines Company's Key Drugs Set for Growth in 2017?
by Zacks Equity Research
On Jul 7, 2017, we issued an updated report on The Medicines Company (MDCO).